This clinical trial is focused on studying the effects of a treatment for people with osteoporosis and osteopenia, which are conditions that cause bones to become weak and more likely to break. The treatment being tested includes a medication called dasatinib, which is taken as a film-coated tablet. Dasatinib is known as a protein kinase inhibitor, which means it works by blocking certain proteins that can affect cell growth. In this study, dasatinib is combined with either quercetin or nicotinamide riboside, which are substances that may help improve bone health.
The purpose of this study is to investigate how effective and safe this combination treatment is in reducing bone loss in patients with low bone mass. Participants in the study will be randomly assigned to receive either the treatment or a placebo. The study will last for a period of 20 weeks, during which time participants will take the medication orally. Throughout the study, researchers will monitor changes in markers that indicate bone resorption, which is the process where bone is broken down and its minerals are released into the bloodstream.
By the end of the study, researchers aim to understand how the treatment affects bone health, specifically looking at markers like CTX, which is a circulating marker of bone resorption, and other markers related to bone formation. This information will help determine if the combination of dasatinib with quercetin or nicotinamide riboside can be a beneficial treatment for individuals with osteoporosis or osteopenia.



Denmark